Our findings demonstrated that compared to treatment with deucravacitinib alone, Deu@PEPS is more effective in ameliorating the induction of multiple cytokines and important molecular features associated with psoriasis by STAT3-Krt17-Cyclin D1 pathway. Here, STAT3 is linked to psoriasis.